A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS (ATAMS)

Merck Serono the Netherlands - a division of Merck BV0 个研究点目标入组 7 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 7

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•All subjects must satisfy the following entry criteria prior to baseline/SD1 (the first
•day of dosing):
•1. Diagnosis of Relapsing Multiple Sclerosis (per McDonald criteria, 2005);
•2. Fulfill at least one of the following: two or more documented relapses during the
•previous 2 years, one or more documented relapses in the year before enrolment, or one or more Gd- enhancing lesions detected on MRI at screening.
•3. Male or female between 18-60 years old, at the time the informed consent is obtained.
•4. Have an EDSS from 0-5.5, inclusive.
•5. Women of childbearing potential must not be breast feeding and have a negative
•serum/urine pregnancy test at initial screening and at Study Day 1 (SD1) before
•dosing. For the purposes of this trial, a woman of childbearing potential is defined as: *All female subjects after puberty unless they are post-menopausal for at least two
•years, or are surgically sterile*.
•6. Female subjects of childbearing potential must be willing to avoid pregnancy by
•using an adequate method of contraception for approximately four (4) weeks prior to SD1, during and for twelve (12) weeks after the last dose of trial medication. This
•requirement does not apply to surgically sterile subjects or to subjects who are
•postmenopausal for at least 2 years. Adequate contraception is defined as two barrier methods, or one barrier method with spermicide or intrauterine device or use of the oral female contraceptive.
•7. Subject is willing and able to comply with study procedures for the duration of the
•8. Voluntarily provide written informed consent (obtained before any trial related
•procedure), including, for USA, subject authorization under Health Insurance
•Portability and Accountability Act (HIPAA), prior to any study-related procedure that
•is not part of normal medical care, and with the understanding that the subject may
•withdraw consent at any time without prejudice to their future medical care.

排除标准

•To be eligible for inclusion in this study the subjects must not satisfy any of the
•following criteria:
•1. Have primary progressive MS.
•2. Have secondary progressive MS without superimposed relapses.
•3. Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator, constitute a risk or a contraindication for the participation in the study or that could interfere with the study objectives, conduct or evaluation.
•4. Prior treatment with B cell modulating therapies, such as rituximab or belimumab.
•5. Exposure to immunomodulatory therapy, such as interferon beta or glatiramer acetate, within 3 months prior to SD1.
•6. Discontinuation of prior immunodulatory therapy due to perceived lack of efficacy.
•7. Prior exposure to immunosuppressive or cytotoxic agents including but not restricted to cladribine, mitoxantrone, alemtuzumab cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, or natalizumab.
•8. Prior myelosuppressive / cytotoxic therapy, such as lymphoid irradiation, or bone
•marrow transplantation.
•9. Prior use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIg) or plasmapheresis within 6 months prior to SD1.
•10. Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days prior to SD1.
•11. Require chronic or monthly pulse corticosteroids during the study
•12. Participation in any interventional clinical trial within 2 months prior to SD1, or within 5 half-lives of the investigated compound, whichever is longer.
•13. Allergy or hypersensitivity to atacicept or to any of the components of the formulated atacicept.
•14. Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).
•15. Moderate to severe renal impairment (creatinine clearance <50ml/min according to Cockcroft-Gault equation).
•16. Allergy or hypersensitivity to gadolinium.
•17. History or presence of uncontrolled or New York Health Association (NYHA) class 3 or 4 congestive heart failure Please add definition.
•[NYHA class 3: Cardiac disease resulting in marked limitation of physical activity. Subjects are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnoea, or anginal pain.
•NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort.
•Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased. (Source: The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston,
•Mass: Little, Brown & Co; 1994:253-256.)];
•18. History of cancer, except adequately treated basal cell carcinoma of the skin, cervical
•dysplasia or carcinoma in situ of the skin or the cervix.
•19. Aspartate aminotransferase (AST) alanine aminotransferase (ALT) or alkaline
•phosphatase (AP) level >2.5 x ULN. Total bilirubin >1.5 x ULN at screening.
•20. Clinically significant abnormality in any haematological test (e.g. haemoglobin <100 g/L (6,21 mmol/L), WBC <3*109/L, lymphocytes < 0.8*109/L, platelets <140*109/L) at screening.
•21. Clinically significant abnormality on chest X-ray performed within 3 months prior to SD1 or on ECG performed at screening.
•22. Immunisation with live vaccines w

研究者

发起方

Merck Serono the Netherlands - a division of Merck BV

相似试验

进行中（未招募）

不适用

A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis

EUCTR2007-003936-50-CZMerck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany255

进行中（未招募）

不适用

A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisRelapsing multiple sclerosis

EUCTR2007-003936-50-NLMerck Serono International S.A.332

进行中（未招募）

不适用

A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 13.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2007-003936-50-GBMerck Serono S.A. - Geneva255

进行中（未招募）

不适用

EUCTR2007-003936-50-SEMerck Serono Geneva- an affiliate of Merck KGaA, Darmstadt Germany255

进行中（未招募）

1 期

EUCTR2007-003936-50-FRMerck Serono International S.A.332